Research
Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC
Nature · By Diana Romero ·
The Brief
- Published online in Nature Reviews Clinical Oncology on 9 November 2026, with DOI 10.1038/s41571-026-01233-z.
- The article's headline reports that divarasib outperforms first-generation KRAS-G12C inhibitors in non-small cell lung cancer (NSCLC).
- The source material provided here gives only the headline and citation, so trial design, sample size and effect sizes are not available.
Why it matters
It reports a comparison between a newer KRAS-G12C inhibitor and earlier agents in NSCLC, which bears on treatment choices and future trial design in this patient population.
Who’s affected
- oncologists and lung cancer researchers
- drug developers working on KRAS-G12C inhibitors
- #kras
- #nsclc
- #oncology
- #divarasib
- #lung-cancer
Nature Reviews Clinical Oncology, Published online: 09 November 2026; doi:10.1038/s41571-026-01233-z Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC
Timeline
Article published online in Nature Reviews Clinical Oncology
nature.com
Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC